[Correspondence] Proton-pump inhibitors and glecaprevir plus pibrentasvir in HCV infection – Authors' reply

Conclusions cannot be reached given the small sample size of the subpopulation of patients receiving proton-pump inhibitors in only one study.

Source: The Lancet Infectious Diseases - November 23, 2017 Category: Infectious Diseases Authors: Xavier Forns, Federico J Mensa Tags: Correspondence Source Type: research